Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news that it acquired a ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds ...

根据协议条款，Rallybio有资格获得750万美元的前期股权，在启动额外临床前研究时获得1250万美元的或有股权支付，以及在Phase 1临床研究开始给药时获得500万美元的里程碑付款。Rallybio还将获得未来净销售额的低个位数百分比的特许权使用费。

康涅狄格州纽黑文 - 目前股价接近0.34美元的临床阶段生物技术公司Rallybio Corporation (NASDAQ: RLYB )已同意将其在REV102（一种用于低磷酸酶症 (HPP)的临床前ENPP1抑制剂）中的权益出售给合资伙伴Recursion Pharmaceuticals，交易金额最高达2500万美元。根据 InvestingPro ...

Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor ...

每经AI快讯，6月24日，英伟达持仓概念股集体上涨，Nebius涨近7%，Recursion Pharmaceuticals涨近6%，CoreWeave涨超3%。

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...